487PAfatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma.

Autor:	Chai, C S1 (AUTHOR), Liam, C K2 (AUTHOR), Lin, O Po3 (AUTHOR), Pang, Y K4 (AUTHOR), Ho, G F5 (AUTHOR), Alip, A6 (AUTHOR), Wong, C K2 (AUTHOR), Poh, M E2 (AUTHOR), Tan, J L2 (AUTHOR)
Zdroj:	Annals of Oncology. 2019 Supplement, Vol. 30, pN.PAG-N.PAG. 1p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu